Improved druggability of gambogic acid using core-shell nanoparticles.

Area of Science:

• Nanomedicine
• Drug Delivery
• Materials Science

Background:

• Gambogic acid (GA) is a promising natural antitumor agent.
• GA's clinical use is limited by poor solubility, stability, and pharmacokinetics.
• Novel nanocarriers are needed to improve GA's therapeutic potential.

Purpose of the Study:

• To develop core-shell hybrid nanoparticles for enhanced gambogic acid (GA) delivery.
• To improve GA's solubility, stability, and tumor-targeting capabilities.
• To evaluate the enhanced antitumor efficacy and safety of GA-loaded nanoparticles.

Main Methods:

• Fabrication of core-shell nanoparticles using benzylamidated poly(γ-glutamic acid) (BzPGA) core and hyaluronic acid-all-trans retinoic acid (HA-C6-ATRA) shell.
• Encapsulation of GA into BzPGA core via π-π stacking interactions.
• Characterization of nanoparticle size, encapsulation efficiency, stability, release profile, and in vivo performance.

Main Results:

• Sub-100 nm core-shell nanoparticles achieved nearly 100% encapsulation efficiency for GA.
• Nanoparticles demonstrated excellent GA protection, sustained release, and improved aqueous formulation.
• In vivo studies showed prolonged circulation, enhanced tumor targeting, and increased antitumor activity of GA without higher toxicity.

Conclusions:

• The developed core-shell nanoplatform significantly enhances the druggability of gambogic acid (GA).
• This nanocarrier system offers a promising strategy for improving the therapeutic index of natural antitumor agents.
• The study provides a valuable model for developing advanced nanomedicines for cancer therapy.